Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, presents the subgroup analysis of the phase 2 SPRINT trial at the 20th Congress of the European Hematology Association (EHA). This results showed that lenalidomide, an immunomodulator, provided clinically significant improved activity irrespective of baseline demographics or disease characteristics when compared with investigator’s choice in patients with relapsed or refractory mantle cell lymphoma.